Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/09/18Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
CINCINNATI--(BUSINESS WIRE)--Feb. 9, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today the completion of patient enrollment in the company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate AKB-9778 for patients with moderate to severe non-proliferative diabetic ret... 
Printer Friendly Version